SBO of PhlexGlobal backed by Bridgepoint Development Capital

Deal typeM&A & Private Equity
IndustryLife Sciences & Manufacturing

BDO is pleased to announce that our M&A team acted as lead adviser to the shareholders of the PhlexGlobal group of companies ("PhlexGlobal") on the successful sale of the business to Bridgepoint Development Capital, a leading European focused private equity house. The deal was completed on 11th July for £42m.  

Phlexglobal, backed by Inflexion Private Equity in 2011, is the leading, worldwide specialist in trial master files (TMF’s) as a result of its high quality service offering, depth of experience and flexibility to work with a wide range of clients. Its specialised cloud based software has facilitated growth in Phelxglobal’s client base to include 37 of the top 50 pharmaceutical companies in the world, including 16 of the top 20, since 2007. The sale is BDO’s second transaction with Phlexglobal having previously advised on the sale to Inflexion Private Equity Partners LLP.   BDO also undertook vendor due diligence and provided tax advice to the vendors.            

"This was a fantastic effort from the BDO team. What really impressed was their knowledge of the industry and contacts in the market, which helped secure a great deal for the shareholders. I would highly recommend BDO. It comes as no surprise that they are building such a reputation for their expertise in the pharma sector".   

Steve Kent, Non Executive Chairman, Phlexglobal